Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

BBP vs PBE overlap: 16% of top holdings shared

Bottom line

How much do BBP and PBE overlap?

16% of their top holdings overlap by weight. 5 securities appear in both funds' top 25, making up 8.3% of BBP's assets and 17.9% of PBE's. They are substantially different portfolios, so owning both adds real diversification.

BBP holds far more positions (70 vs 33), so it is broader beyond the top names.

Updated Nov 22, 2026

Overlap at a glance

BBPPBE
Weight overlap (top 25)16%
Shared holdings5
Weight in shared holdings8.3%17.9%
Total positions7033
Expense ratio0.34%0.59%
Holdings as ofJul 31, 2026Jul 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Holdings BBP and PBE have in common

Holding% of BBP% of PBEOverlap
Regeneron Pharmaceuticals REGN1.72%5.47%1.72%
Protagonist Therapeutics Inc PTGX1.71%3.40%1.71%
Acadia Pharmaceuticals Inc ACAD1.69%3.02%1.69%
Halozyme Therapeutics Inc HALO1.64%2.98%1.64%
Incyte Corp INCY1.52%3.06%1.52%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in BBP

  1. Crinetics Pharmaceuticals Inc — 3.34%
  2. Kiniksa Pharmaceuticals International Plc — 1.97%
  3. Verastem Inc — 1.95%
  4. Precigen Inc — 1.94%
  5. Omeros Corp — 1.87%
  6. Nuvation Bio Inc — 1.77%
  7. Bridgebio Pharma Inc — 1.65%
  8. Beone Medicines Ltd — 1.65%
  9. Xeris Biopharma Holdings Inc — 1.64%
  10. Liquidia Corp — 1.63%
  11. Immunocore Holdings Plc — 1.61%
  12. Ironwood Pharmaceuticals Inc — 1.60%
  13. Arrowhead Pharmaceuticals Inc — 1.56%
  14. Roivant Sciences Ltd — 1.55%
  15. Ligand Pharmaceuticals — 1.55%

Only in PBE

  1. Invesco Private Prime Fund — 12.89%
  2. Amgen Inc. — 5.22%
  3. CareDx, Inc. — 5.04%
  4. Vertex Pharmaceuticals Inc. — 4.99%
  5. Invesco Private Government Fund — 4.97%
  6. Royalty Pharma PLC — 4.94%
  7. Biogen Inc. — 4.79%
  8. Gilead Sciences, Inc. — 4.43%
  9. United Therapeutics Corp. — 4.08%
  10. Bio-Techne Corp. — 3.73%
  11. Illumina, Inc. — 3.51%
  12. Vericel Corp. — 3.27%
  13. Alnylam Pharmaceuticals, Inc. — 3.17%
  14. Repligen Corp. — 3.04%
  15. Qiagen N.V. — 2.89%

Asset mix

Asset typeBBPPBE
Stocks99.8%100.1%
Cash & short-term funds0.7%17.9%

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Country mix

CountryBBPPBE
US84.6%108.6%
GB3.6%4.9%
KY3.6%1.6%
CH3.0%—
NL—2.9%
BM1.6%—
DK1.5%—
DE1.4%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / Jul 31, 2026)

Check another pair

FAQ

How much do BBP and PBE overlap?
About 16% by weight. 5 securities appear in both funds' top 25 holdings; they make up 8.3% of BBP's assets and 17.9% of PBE's. They are substantially different portfolios, so owning both adds real diversification.
What stocks do BBP and PBE have in common?
The largest shared holdings are Regeneron Pharmaceuticals, Protagonist Therapeutics Inc, Acadia Pharmaceuticals Inc, Halozyme Therapeutics Inc, Incyte Corp.
Should I own both BBP and PBE?
Their portfolios are mostly different, so owning both can add diversification. Check how each fits your overall allocation.
Which holds more stocks, BBP or PBE?
BBP is broader, with 70 positions versus 33 for PBE. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.